Pre-made Dalutrafusp Alfa benchmark antibody (Bispecific, anti-NT5E/CD73;TGFB1;TGFB3 therapeutic antibody, Anti-eN/NTE/eNT/CALJA;CED/DPD1/IBDIMDE/LAP/TGF-beta1/TGFbeta;ARVD/ARVD1/LDS5/RNHF Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Dalutrafusp Alfa benchmark antibody (Bispecific, anti-NT5E/CD73;TGFB1;TGFB3 therapeutic antibody, Anti-eN/NTE/eNT/CALJA;CED/DPD1/IBDIMDE/LAP/TGF-beta1/TGFbeta;ARVD/ARVD1/LDS5/RNHF Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dalutrafusp alfa is a bispecific antibody-fusion protein that was designed as a checkpoint modulator for immuno-oncology. It was invented by Agenus (as AGEN-1423), and has been licensed to Gilead for clinical development (as GS-1423). The antibody portion of dalutrafusp targets the adenosine degrading enzyme ecto-5′-nucleotidase (NT5E/CD73; produces an immunosuppressive effect in the tumour micoenvironment), and this is fused via a peptidyl linker to the extracellular domain of transforming growth factor beta receptor 2 (TGFBR2) which acts as a molecular trap for both TGF¦Â1 and TGF¦Â3. NT5E and TGF¦Â are two significant resistance pathways that allow tumours to escape immune surveillance.